TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03423771

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NPF-08
Description: Drug: NPF-08 Arms: NPF-08 oral sulfate solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NPF-08
Description: Drug: NPF-08 Arms: NPF-08 oral sulfate solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NPF-08
Description: Drug: NPF-08 Arms: NPF-08 oral sulfate solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NPF-08
Description: Drug: NPF-08 Arms: NPF-08 oral sulfate solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NPF-08
Description: Drug: NPF-08 Arms: NPF-08 oral sulfate solution
Study: NCT03641365

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test group
Description: Guided Implant placement Positioning/placement of dental implants thought the fully acrylic surgical template without metallic sleeves.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: Guided Implant placement Positioning/placement of dental implants thought the acrylic surgical template with metallic sleeves.
Study: NCT00671060

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: 200 mcg buccal misoprostol administered every 6 hours for up to 48 hours until fetus is delivered.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Misoprostol
Description: 100 mcg buccal misoprostol administered every 6 hours for upto 48 hours
Study: NCT01773369

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early leg training
Description: Children will engage in \~1 hour/day, 4 days/week treatment for 3 months. The treadmill will consist of supported walking on a treadmill, over ground, stair climbing, standing, kicking, splashing ... etc. leg activity. Activities will be directed by a physical therapist in the clinical setting.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Delayed leg training
Description: The training activity will be exactly the same as the Early leg training group, except that it will occur \~3 months after recruitment.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent leg training
Description: Children will engage in \~1 hour/day, 4 days/week treatment for 3 months. The treadmill will consist of supported walking on a treadmill, over ground, stair climbing, standing, kicking, splashing ... etc. leg activity. Activities will be directed by parents in their home or community environment.
Study: NCT05513911

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acute Intermittent Hypoxia
Description: Acute Intermittent Hypoxia is administered in 30-60 second bouts of 9% O2 concentration, followed by 60-90 seconds of normoxic air concentrations (21% O2, room air). This procedure is repeated 15 times for a 30 minute session
Study: NCT01503424

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: Olanzapine Tablets, 5 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olanzapine
Description: Olanzapine Tablets, 5 mg
Study: NCT02016118

Intervention type: DEVICE
Intervention: Ialuril
Description: The treatment is an intravesical administration of combined hyaluronic acid (HA) 1.6% and chondroitin sulphate (CS) 2.0% once per week for the first month, followed by one instillation every two weeks for the second month and one instillation per month until stable remission of the symptoms.
Study: NCT01516099

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: General Practitioners
Description: The general practitioner can refer his patients to a physical activity counselor for an individual coaching (intake session with development of program and pretesting, follow up by e-mail or phone (max 4x), personal contact moments (max 3x) and exit session with evaluation and posttesting).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Social-cultural organizations
Description: In the social-cultural organization, members can sign in for group sessions led by the physical activity counselor (intake session with development of program and pretesting, follow up by email or letters (max 4x), personal contact moments (max 4x) and exit session with evaluation and posttesting).
Study: NCT03320915

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol
Description: Cholecalciferol 5mg (200,000 IU) up to maximum of three times during 1 year follow-up period according to measured 25(OH)D3 level.
Study: NCT01146483

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin, Pantoprazole
Description: Rosuvastatin, 10 mg tablets, single dose on the morning~Concomitant drug: Pantoprazole; 40 mg tablets, 2 single doses administered 1 hour before rosuvastatin and 23 hours after rosuvastatin administration. A placebo is given on the other period as a crossover design study.
Study: NCT01587989

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: 15-25 mg orally weekly, Weeks 1-12

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methotrexate
Description: 15-25 mg orally weekly, Weeks 13-24

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: methotrexate placebo orally weekly, Weeks 13-24

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tocilizumab [RoActemra/Actemra]
Description: 8 mg/kg iv every 4 weeks, 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tocilizumab [RoActemra/Actemra]
Description: 8 mg/kg iv every 4 weeks, 24 weeks
Study: NCT02421250

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radical-7 Noninvasive Hgb Monitor
Study: NCT01261403

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PDA001
Description: Dose escalation study: Subjects will be assigned to 1 of 2 treatment groups (1 unit or 4 units vs. vehicle control) based on the order in which they enroll in the study. Intravenous infusion will be administered on days 0 and 7. Nonresponders will be unblinded after 12 weeks of study. Non- responders on vehicle control will be re-dosed with the active PDA001 dose assigned at baseline (2 infusions, 7 days apart). Nonresponders taking active PDA001 will enter the safety follow-up portion of the study. Responders at 12 weeks will continue in the safety and efficacy follow-up portion of the study until 12 months of study. Responders will be treated for RA flare between 3-9 months of study with the active PDA001 dose assigned at baseline (2 infusions, 7 days apart).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PDA001
Description: Dose escalation study: Subjects will be assigned to 1 of 2 treatment groups (1 unit or 4 units vs. vehicle control) based on the order in which they enroll in the study. Intravenous infusion will be administered on days 0 and 7. Nonresponders will be unblinded after 12 weeks of study. Non- responders on vehicle control will be re-dosed with the active PDA001 dose assigned at baseline (2 infusions, 7 days apart). Nonresponders taking active PDA001 will enter the safety follow-up portion of the study. Responders at 12 weeks will continue in the safety and efficacy follow-up portion of the study until 12 months of study. Responders will be treated for RA flare between 3-9 months of study with the active PDA001 dose assigned at baseline (2 infusions, 7 days apart).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vehicle Controlled Placebo
Description: Cohort Dose Level 1: 4 units vehicle controlled placebp infused on Day 0 and Day 7~Cohort Dose Level 2: 4 units vehicle controlled placebo infused on Day 0 and Day 7

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vehicle Controlled Placebo
Description: Cohort Dose Level 1: 4 units vehicle controlled placebp infused on Day 0 and Day 7~Cohort Dose Level 2: 4 units vehicle controlled placebo infused on Day 0 and Day 7

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Controlled Placebo
Description: Cohort Dose Level 1: 4 units vehicle controlled placebp infused on Day 0 and Day 7~Cohort Dose Level 2: 4 units vehicle controlled placebo infused on Day 0 and Day 7
Study: NCT02871479

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAN007 5% cream
Description: 5% EISO in a cream formulation applied twice a day for up to 28 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A placebo cream containing the same components as the vehicle for the active intervention arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAN007 10% cream
Description: 10% EISO in a cream formulation applied twice a day for up to 28 days.
Study: NCT01725880

Intervention type: OTHER
Intervention: Observation
Study: NCT05104944

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Serial MRIs
Description: Serial use of MRI at 3, 6, 9 and 12 months to identify disease resolution and thus discontinuation of immobilisation plus standard care.
Study: NCT01331161

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ZOSTAVAX
Description: shingles vaccine, one dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ZOSTAVAX
Description: shingles vaccine, one dose
Study: NCT03542994

Intervention type: OTHER
Group type: OTHER
Intervention: EDP1066
Description: EDP1066 is an orally administered monoclonal microbial

Intervention type: OTHER
Group type: OTHER
Intervention: EDP1066
Description: EDP1066 is an orally administered monoclonal microbial

Intervention type: OTHER
Group type: OTHER
Intervention: EDP1066
Description: EDP1066 is an orally administered monoclonal microbial

Intervention type: OTHER
Group type: OTHER
Intervention: EDP1066
Description: EDP1066 is an orally administered monoclonal microbial

Intervention type: OTHER
Group type: OTHER
Intervention: EDP1066
Description: EDP1066 is an orally administered monoclonal microbial

Intervention type: OTHER
Group type: OTHER
Intervention: EDP1066
Description: EDP1066 is an orally administered monoclonal microbial

Intervention type: OTHER
Group type: OTHER
Intervention: EDP1066
Description: EDP1066 is an orally administered monoclonal microbial

Intervention type: OTHER
Group type: OTHER
Intervention: EDP1066
Description: EDP1066 is an orally administered monoclonal microbial

Intervention type: OTHER
Group type: OTHER
Intervention: EDP1066
Description: EDP1066 is an orally administered monoclonal microbial
Study: NCT03172351

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EDoF2
Description: Comparison EDoF2 IOL

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EDoF2
Description: Comparison EDoF2 IOL
Study: NCT03542994

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo oral capsule
Description: placebo

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo oral capsule
Description: placebo

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo oral capsule
Description: placebo

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo oral capsule
Description: placebo

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo oral capsule
Description: placebo

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo oral capsule
Description: placebo

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo oral capsule
Description: placebo

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo oral capsule
Description: placebo

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo oral capsule
Description: placebo
Study: NCT02760290

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extraperitoneal cesarean section

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intraperitoneal cesarean section
Study: NCT03751332

Intervention type: DRUG
Group type: OTHER
Intervention: Tacrolimus
Description: Conversion from either cyclosporin or tacrolimus to tacrolimus modified release
Study: NCT02594644

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microneedle Roller
Description: The study device (MR200, Clinical Resolutions Laboratory, Inc.) is a disposable roller equipped with stainless steel needles that are 650 micrometers in length.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microneedle Roller
Description: The study device (MR200, Clinical Resolutions Laboratory, Inc.) is a disposable roller equipped with stainless steel needles that are 650 micrometers in length.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aminolevulinic Acid
Description: Levulan® Kerastick® DUSA Pharmaceuticals, Inc., Wilmington, MA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aminolevulinic Acid
Description: Levulan® Kerastick® DUSA Pharmaceuticals, Inc., Wilmington, MA

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Blue Light
Description: Blu-U unit (DUSA Pharmaceuticals, Inc., Wilmington, MA

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Blue Light
Description: Blu-U unit (DUSA Pharmaceuticals, Inc., Wilmington, MA
Study: NCT00960076

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin
Description: 5mg oral tablet once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin XR
Description: 500mg oral tablet once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin XR
Description: 750mg, 2 tablets once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin XR
Description: 750mg, 2 tablets once daily
Study: NCT02126059

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reminiscence
Description: The 10 session topics include Happy to seeing you, Childhood stories, Food flavor, Our old songs, Festival, My family, My Carrier, Unforgettable events, My home, and My award.~small group intervention (8-12 per group), expected total number of group is 5.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive stimulation
Description: The 10 session topics include psycial activities, sound, face, food, word association, number and games, being creative, categorizing objects, orientation, and team qiuz.~small group intervention (8-12 per group), total number of group is 5.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aroma-massage
Description: Researcher will conduct hand and arm massage to a patient, once a week, each time session for 30 mins with natural tested and safe aroma-essential oil.
Study: NCT01878630

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Remote Patient Management
Description: Guideline-based care in heart failure including at least 5 scheduled doctor's visits within 12 months (GP and specialist) plus devices for Remote Patient Management at patient site for daily monitoring of ECG, weight, blood pressure, self-report of health status:~* weighing scale (Seca 861 with bluetooth, seca gmbh \& co. kg.)~* blood pressure device (UA767PBT with bluetooth, A\&D Ltd.)~* ECG-eventrecorder (PhysioMem® PM 1000, getemed Medizin- und Informationstechnik AG)~* patient-communication platform (Physio-Gate® PG 1000, getemed Medizin- und Informationstechnik AG)~* help call device (DORO Easy 510/ Doro HandlePlus 334gsm, doro AB)~at center site:~- electronic patient record (eHealth connect 2.0, T-Systems International)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Guideline-based care in heart failure including at least 5 scheduled doctor's visits within 12 months (GP and specialist)
Study: NCT01211912

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arm 1 (20 patients)
Description: Acetaminophen 1000 mg by mouth once

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arm 2 (34 patients)
Description: Acetaminophen 1000 mg by mouth once
Study: NCT00633399

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ziprasidone
Description: 20mg-80mg a day. Dose increases of 20mg per day may occur at three study visits as directed by clinician. Maximum; 80mg per day per patient.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0mg Placebo per day (1-4 tablets per day). Dose increases and dose decreases may occur, but patient will remain at 0mg placebo.
Study: NCT01960569

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: active product ( Thrombexx) assigned to arm 1
Description: Dispense 2-3 cm of cream or gel, 2-3 times per day and carry out a light massage until complete

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo assigned to arm 2
Study: NCT03723395

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tucatinib
Description: 300mg dose, orally administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tucatinib
Description: 300mg dose, orally administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tucatinib
Description: 300mg dose, orally administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tucatinib
Description: 300mg dose, orally administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tucatinib
Description: 300mg dose, orally administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: itraconazole
Description: 200mg dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rifampin
Description: 600mg dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemfibrozil
Description: 600mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: repaglinide
Description: 1mg dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tolbutamide
Description: 500mg dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: midazolam
Description: 2mg dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: digoxin
Description: 0.5 mg dose
Study: NCT01458002

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tailored Internet Communication with Relational Agent
Description: The Tailored Internet Intervention will include a relational agent component, which is an animated conversational agent that builds a working relationship with subjects over time and uses this alliance to boost intervention effectiveness and retention to the Tailored Internet Communications web site.

Intervention type: OTHER
Group type: OTHER
Intervention: Tailored Internet Communication with Relational Agent
Description: The Tailored Internet Intervention will include a relational agent component, which is an animated conversational agent that builds a working relationship with subjects over time and uses this alliance to boost intervention effectiveness and retention to the Tailored Internet Communications web site.

Intervention type: OTHER
Group type: OTHER
Intervention: Tailored Internet Communications
Description: Best practices for TTM tailored communications with two types of feedback: normative - compared to peers and ipsative - self compared to previous assessment.
Study: NCT01050088

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: sucrose solution
Description: 5cc 5% sucrose solution P/O

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 5cc saline p/o
Study: NCT00987948

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: maraviroc (Selzentry)
Description: dosage varies with other medications being taken; will follow package insert guidelines
Study: NCT01496183

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: Olanzapine 5mg capsule administered orally at bedtime for 7 days followed by Olanzapine 10 mg capsule administered orally at bedtime for 7 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule administered orally at bedtime for 14 days
Study: NCT02170506

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Urostim 2 stimulation
Description: Sensory transcutaneous electrical stimulation will be started for a period of 20 minutes. It is applied by means of two surface electrodes placed under chin stimulation of both sides of the center line of the preceding side. Sensory transcutaneous electrical stimulation will inhibit the cerebral control of swallowing.
Study: NCT02867280

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: red round tablet
Study: NCT01146483

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rosuvastatin, Pantoprazole
Description: Rosuvastatin, 10 mg tablets, single dose on the morning~Concomitant drug: Pantoprazole; 40 mg tablets, 2 single doses administered 1 hour before rosuvastatin and 23 hours after rosuvastatin administration. A placebo is given on the other period as a crossover design study.
Study: NCT02458417

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ReCell
Description: A split-thickness skin biopsy will be taken from the hip region of the patient. The skin biopsy that is obtained will be treated in the ReCell kit (Avita Medical Europe Ltd, Cambridge, UK): it will be placed in the heated enzyme solution, containing trypsin, in the device for 15-20 minutes to allow cell disaggregation. After that period, the biopsy will be taken from the enzyme solution and will be dipped in sodium lactate buffer solution. The biopsy will then be scraped to disaggregate the cells from the dermal epidermal junction. The epidermal cells are drawn up in a syringe. The prepared suspension will be dripped on both donor and acceptor site.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ReCell
Description: A split-thickness skin biopsy will be taken from the hip region of the patient. The skin biopsy that is obtained will be treated in the ReCell kit (Avita Medical Europe Ltd, Cambridge, UK): it will be placed in the heated enzyme solution, containing trypsin, in the device for 15-20 minutes to allow cell disaggregation. After that period, the biopsy will be taken from the enzyme solution and will be dipped in sodium lactate buffer solution. The biopsy will then be scraped to disaggregate the cells from the dermal epidermal junction. The epidermal cells are drawn up in a syringe. The prepared suspension will be dripped on both donor and acceptor site.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ReCell
Description: A split-thickness skin biopsy will be taken from the hip region of the patient. The skin biopsy that is obtained will be treated in the ReCell kit (Avita Medical Europe Ltd, Cambridge, UK): it will be placed in the heated enzyme solution, containing trypsin, in the device for 15-20 minutes to allow cell disaggregation. After that period, the biopsy will be taken from the enzyme solution and will be dipped in sodium lactate buffer solution. The biopsy will then be scraped to disaggregate the cells from the dermal epidermal junction. The epidermal cells are drawn up in a syringe. The prepared suspension will be dripped on both donor and acceptor site.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Full surface CO2 laser 200 mJ
Description: Full surface pretreatment with the CO2 laser (Ultrapulse, ActiveFX handpiece, Lumenis Inc., Santa Clara, CA, USA) at 200 mJ (depth 144 µm) and density 3

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Full surface CO2 laser 150 mJ
Description: Full surface pretreatment with the CO2 laser (Ultrapulse, ActiveFX handpiece, Lumenis Inc., Santa Clara, CA, USA) at 150 mJ (depth 144 µm) and density 3

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fractional CO2 laser 7.5 mJ, 20%
Description: Pretreatment with the fractional CO2 laser (Ultrapulse, DeepFX handpiece, Lumenis Inc., Santa Clara, CA, USA) at 7.5 mJ/microbeam (depth 225 µm) and 20% density.